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Introduction: An inhibitory serum factor of mixed Iymphocyte culture (MLC) has been associated with successful pregnancy after.
Iymphocyte transfusion in women with unexplained recurrent spontaneous abortions (ASA). Objective: Investigate whether the
inhibitory serum factor of MLC is essential for a successful pregnancy. Method: Sera from 33 healthy pregnant women and from 40
women with ASA were assessed by a one-way MLC in which the woman's Iymphocytes were stimulated with her partner's Iymphocytes
or with third.party Iymphocytes. Results: An inhibitory serum effect (inhibition > 50% as compared to normal serum) was detected in
45% of the pregnant women who had at least 1 previous parity, in 80/0 of the primigravidea, in 29% of those with one abortion and in
58% of those with more than one abortion. Conclusion: ,MLC inhibitory serum factor does not seem to be an essential factor for
pregnancy development. Therefore, it should not be considered as a parameter for the assessment of ASA patients.
UNITERMS: Mixed Iymphocyte culture testePregnancy. Habitual abortion.
INTRODUCTION
The maternal immunologic response to the fetus hasbeen assessed in several studies.I-4 However,the essential factors that lead to the establishment
and maintenance of successful pregnancy remain unclear.
It has been suggested that in a normal pregnancy there is a
modulation of potentially deleterious immune responses
against the fetus in order to prevent rejection reactions.5,6
Thus, an abnormal allogeneic response, with insufficient
production of blocking factors, has been proposed as the
cause of certain unexplained recurrent spontaneous
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abortions (RSA).1-3,6In order to induc~ an adequate maternal
immune response, these patients have been immunized with
paternal or third party donor leukocytes.3,7-1O
The mixed lymphocyte culture (MLC). is an in vitro
model for allegeneic T cell proliferati ve response that has
been used to detect blocking factors in maternal serum.
Several investigators reported an inhibitory serum effect
upon the autologous lymphoproliferative response to the
partner's lymphocytes in women with successful pregnancy
and its absence in RSA patients.3,5,6Therefore, it has been
suggested that the absence of this factor may predispose to
abortion.1,2,1~Moreover, its determination has been adopted
as a parameterío select3,9,11and to assess RSA patients that
receive leukocyte transfusions.2,9,12-14This factor has been
observed in transfused RSA patients, 2,9,11,15but çontroversial
results have been reported regarding its association with a
subsequent successful pregnancy.2,1O,12,13,15-17
The MLC inhibitory serum factor has been assessed
mostly in non-pregnant women with a successful obstetric
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RESULTS
Figure 1 - Percentage of pregnant women and patients with
unexplained recurrent spontaneous abortions (ASA) that presented
mixed Iymphocyte culture (MLC) inhibitory serum factor.
Fisher's exact test: primigravidae x 1 previous pregnancy: p = 0,049;
primigravidae x primary aborters: NS; primigravidae x secondary
aborters: p = 0,01 ;primary aborters x secondary aborters: p = 0,01.
An inhibitory activity on the mixed lyrnphocyte culture
involving the maternal lyrnphoproliferative response to
partner's cells was observed in the sera of 45% (9/20) ofthe
pregnant women who had at least one parity and in only 8%
(1/13) ofthe primigravidae (p < 0.05) (Fig. 1). The frequency
of the inhibitory factor in the sera ~f pregnant women with
one previous pregnancy (3/6) did not differ from that observed
in pregnant women with more than one previous pregnancy
(6/14). Fifteen patients were assessed during the frrst, 14
during the second and four during the third trimester of
pregnancy and the serum factor was detected with the same
frequency in the three trimesters of pregnancy.
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automated harvester '(T.itertek Cell Harvester) and
processed for [3H]thymidine uptake scintillation counting.
The presence of an inhibitory factor in the serum was
defined as a decrease of at least 50% of the counts in
cultures with the experimetnal serum' as compared to the
mean counts observed with the controI serum.
3. Phytohemagglutinin (PHA) stimulated cultures:
PeripheraI blood mononuclear cells (lxl05) were incubated
in culture rnedium with PHA (Difco, Detroit, USA) at a
concentration of 10 rng/mI, for three days. The cultures
were set up in triplicates, with 20% of experimental or
controI sera. Otherwise, the method was the same as the
one described for the MLC.
4. Statistical analysis: Data were analysed by the
Fisher's exact test.and a p value < 0,05 was taken as the
leveI of significance.
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MATERIAL AND METHODS
history and in RSA patients.IO,1l,13,14,16,18 In the present study
we have assessed the sera of healthy pregnant women and
of non- transfused RSA patients, in order to determine
whether this factor is essential to the development of a
normal pregriancy and to investigate whether its absence
could be considered a relevant parameter for the diagnosis
and therapeutic orientation of RSA patients.
1. Patients: The study comprised 33 pregnant women
with normal obstetric histories and 40 non-pregnant
women with recurrent spontaneous abortions (RSA).
Thirteeen of the pregnant women were primigravidae and
the others had 1 to 6 previous pregnancies. They were
assessed in different trimesters of pregnancy. RSA was
defined as three or .more successive miscarriages in the
first trimester of pregnancy in women without evidence
of uterine abnormalities, genital-tract infections, hormonal
deficiencies or autoantibodies. Chromosome abnormalities
were not detected in the patients or their partners. RSA
patients were classif~ed as primary or secondary aborters
on the basis of their obstetric histories. The women who
had never had a viable pregnancy were considered to be
primary aborters, whereas women who had already had a
live birth or stillbirth with more than 20 weeks of gestation
were classified as secondary aborters.
None of the women assessed in this study had a
history of previous blood transfusion. Informed consent
to participate in the study was obtained from all couples.
This study was conducted at the Immunology Laboratory
of tlie Allergy, ClinicaI Immunology and Rheumatology
Division - Department of Pediatrics of UNIFESP.
2. Mixed lymphocyte culture: Mononuclear cells
were separated from peripheraI blood using a Ficoll-
Hypaque density gradiente The one-way MLC test was
performed with 1 x 105 responder ceIIs and 1 x 105
Mitomycin C treated stimulator cells in RPMI-1640
\Slgma, St. Louis, Mo) culture medium supplemented with
HEPES, L-glutamine, non-essential amino acids, sodium
bicarbonate and gentamicin. The cultures were carried
out in triplicates, in the presence 20% controI serum (pooI
of male donor sera) or 20% serum being assessed for the
presence of an MLC inhibitor factor. All sera were heat
inactivated, at 56° C for 30 minutes. The cells were
incubated at 37° C in a 5% CO2 atmosphere for 6 days.
Eighteen hours before termination, the cultures were
labeled with 2 mCi of [3H]thymidine (specific activity
2.48 x lO" Bq/mmol). The cells were retrieved using an
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Figure 2 - Percentage of sera that presented an inhibitory effect
in a mixed Iymphocyte culture (MLC) performed with Iymphocytes
from HLA c1ass II incompatible donors.
* with normal obstetric history.
frequencies of sera with a suppressive effect were observed
among pregnant women (45%), secondary aborters (40%)
and non-pregnant women with at least one previous pregnancy
(43%). Only 1 out of 9 (11%) of the nulliparae sera (p =
0,11 when compared to the above mentioned groups) and
none of the male sera presented a suppressive effect (Fig. 2).
% of sera that presented MLC inhibitory factor
504030,2010
pregnant women
n = 20
o
secondary aborters
n=5
non-pregnant women
with previous pregnancy
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Among RSA patients, 29 % ofthe primary and 58% of
the secondary RSA patients presented the inhibitory serum
factor (Fig. 1), with an overall incidence of 38%. The
difference in incidence of inhibitory factor between primary
and secondary aborters was not statistically significant (p =
0.09). However, the incici.ence of the inhibitory factor was
significantly higher among secondary (p = 0.01), but not
among primary aborters, when compared to primigravidae
women. No significant differences were detected regarding
the incidence of this serum factor in the primary or secondary
RSA patients when they were compared to pregnant women
with at least one previous pregnancy.
A suppressive effect of the serum on the maternal
lumphoproliferative response to third party lymphocytes
was observed in ,40% of the non-primigravidae pregnant
women, in 21% of the primary aborters and in 25% of the
secondary aborters. With few exceptions-, the sera that
inhibited the response to third party cells also inhibited
the response to partner's cells (Table 1).
The suppressi ve effect of sera from different sources
was also investigated in a one-way MLC performed with cells
from two HLA (human leukocyte antigens) class II
incompatible donors, not including cells from the partner or
from the individuals whose sera were being tested. Similqr
Table 1
Percentage of pregnant women with at least one
previous pregnancy and women with recurrent
unexplained spontaneous abortions (RSA) that
presented inhibitory serum facto r in mixed
Iymphocyte cultures (MLC) performed with
different cell combinations.
An inhibitory serum effect on the PHA-induced
lymphoproliferative response was observed in only
10% (3/29) of the pregnant women, and in 5% (1/20)
of RSA patients.
DISCUSSION
Responder 8timulator Pregnant Primary 8econdary
cells cells women aborters aborters
20% ** 8% ** 22% **
F - female; P - partner; T - third party
Fm, Pm, Tm - mytomicin treated cells
* Percentage of women who presented inhibitory serum tactor both
in cultures with Pm and with Tm as stimulator cells
** Percentage of women who presented inhibitory serum tactor
both in cultures with P and with T as responder cells.
.F
F
P
T
Pm
Tm
Fm
Fm
n = 20 n = 18 n = 12
45% 29% 58%
40% 21 % 250/0
40%* 14%* 25%*
n = 20 n = 13 n=9
20% 15% 22%
35% 8% 33%
The investigation of a factor in the serum of women
with a successful pregnancy history and from RSA patients
capable of inhibiting the in vitro proliferative response of
maternal to paternal cells (MLC) has been the focus of
many studies published over the last few years. Regarding
RSA patients, the absence of this factor was considered
,by Mclntyre et aI.3 as a characteristic of primary aborters
for whom immunization with the partner's leukocytes
would be indicated. On the other hand, according to these
same authors, in secondary aborters, a group that would
benefit from heparin therapy, this factor is only present in
a fraction of the cases. In the present study an inhibitory
activity of the serum was detected in 29% of the primary
aborters and in 58% of the secondary, clearly showing that
the absence of this factor cannot be. used as a distincti ve
marker for primary aborters.
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Another aspect that has drawn attention to the MLC
inhibitory serum factor has been its potential to predict
the outcome of a pregnancy folIowing the immunization
with parentalleukocytes. Some authors have found that
the development of this factor could be considered
predictive of a successful pregnancy 2,4,5,8,11,12, while others
have not found such a correlation. 10,14-16 We reasoned that
if this factor is biologicalIy important for the development
of a successful pregnancy, it should regularly be detected
in the serum from pregnant women. The present data show
that this is not the case, since the inhibitory factor was
detected in only 1 out of 13 primigravidae, alI of whom
have already delivered a healthy baby. Furthermore, a
similar incidence of the inhibitory factor was observed in
pregnant women who had at least one previous parity
(45%) and in secondary aborters (58%). We believe that
these results, taken together, support the contention that
the inhibitory factor should be regarded as an
epiphenomenon of pregnancy rather than an important
factor for fetal survival, as has already been suggested.5,18
The nature of the MLC inhibitory factor is not yet
fully clarified. It has been suggested that the blocking
activity may be related to antibodies directed against HLC
antigens or against trophoblast antigens that cross-react
with HLA antigens, or could represent anti-idiotype
antibodies directed to the T celI receptors (TCR) involved
in alIorecognition. Our study was not specifically designed
to study the nature of the inhibitory factor, but we have
addressed the question concerning its specificity in
blocking the response of the pregnant or RSA women
against their partners' celIs. Results have shown that the
majority of the sera that inhibited the cultures with the
partner cells also showed inhibition in cultures with other
cell combinations (Table 1 and Fig. 2), confirming
observations of other authors.2,6 It is interesting to note
that no inhibitory activity was detected in any of the mal e
sera tested, as already reported in medicalliterature.6 When
the women's sera were assayed in PHA-stimulated cell
cultures, only a few (three out of 29 pregnant and one out
of 20 RSA) showed an inhibitory effect. Thus it appears
that the inhibitory factor somehow interferes with
allorecognition or, alternatively, that is is not powerful
enough to block the response to mitogens that represent a
stronger stimulus than allogeneic cells.
CONCLUSION
Our data suggest that the MLC inhibiting factor should
be regarded as a consequence of pregnancy rather than an
essential factor for fetal survi vaI. Therefore, we believe that
this test, which is costly, is not informative either regarding
the decision to immunize RSA women with parental
leukocytes or as a predictor of a successful pregnancy in
women submitted to immunization. It is therefore our
opinion that the only immunological test that should be
performed in RSA patients that are being considered for
entering an immunization protocol is the search for
lymphocytqtoxic antibodies against the cells (crossmatch)
that will be used for immunization. A positive crossmatch
should contraindicate the immunization in order to avoid
hypersensitization and also because, as noted by some
authors, 10 a positive crossmatch is already an indication that
an immune response to paternal antigens has occurred.
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